Antibodies - COVID-19 antibody ELISA kit
Can't see this email? View it online
   
  Antibodies  
  The latest antibodies news from News Medical  
 

VHH Antibodies (Nanobodies) Advantages and LimitationsFree Immunodetection Webinar

Please register for Sino Biological-hosted webinar Apr 29th at 2PM EST: High-content Multiparametric Antibody Screening for Specificity and Function with AbTheneum™. During this webinar, you’ll learn more about AbTheneum™, one of the most sophisticated single B cell approaches for antibody discovery.

Register for the free webinar now
 
 
    KeysightCOVID-19 antibody ELISA kit
 
The Kantaro COVID-SeroKlir kit available from EKF Diagnostics is a direct ELISA designed for the quantitative detection of human IgG antibodies to the SARS-CoV-2 virus in samples of serum and plasma (K2-EDTA/Li-Heparin). The COVID-SeroKlir obtained FDA Emergency Use Authorization (EUA) in November 2020 and a CE mark in October 2020.
 
Learn More
 
 
   Cytosections for Antibody Screening and Immunohistochemistry Protocol DevelopmentCytosections for Antibody Screening and Immunohistochemistry Protocol Development
 
AMSBIO has launched a comprehensive range of cytosections that offer a verified, reproducible and renewable source of positive/negative controls where the expression of the target biomarker is confirmed for accuracy and specificity by an immunoassay.
 
 High antibody and inflammatory mediator levels may predict severe COVID-19
 
High antibody and inflammatory mediator levels may predict severe COVID-19A new study reports on biomarkers could help predict the progression of the viral illness to dangerous levels early enough to enable timely intervention.
 
 
 Study reveals how some antibodies can effectively disable ebolaviruses
 
Study reveals how some antibodies can effectively disable ebolavirusesSome survivors of ebolavirus outbreaks make antibodies that can broadly neutralize these viruses--and now, scientists at Scripps Research have illuminated how these antibodies can disable the viruses so effectively. The insights may be helpful for developing effective therapies.
 
 
 Early monoclonal antibody therapies beneficial for COVID-19, finds study
 
Early monoclonal antibody therapies beneficial for COVID-19, finds studyA team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate COVID-19. The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19.